| Autor: |
de Melo Vilar, Kamila, Cristiny Pereira, Michelly, Tavares Dantas, Andrea, Jesus Barreto de Melo Rêgo, Moacyr, da Rocha Pitta, Ivan, Diniz Lopes Marques, Claudia, Silva Guimarães Gonçalves, Rafaela, Ferreira da Rocha Júnior, Laurindo, Luzia Branco Pinto Duarte, Ângela, Galdino da Rocha Pitta, Maira |
| Zdroj: |
Autoimmune Diseases; 2019, Vol. 2019 Issue: 1 |
| Abstrakt: |
Background. Due to the variety of functions that galectins (Gal) possess, it is clear that they participate in the pathogenesis of rheumatoid arthritis (RA). Although some studies demonstrate their functions, there is still no correlation with the clinical data of the disease, having the physiological meaning still unknown. Objectives. To compare serum levels of Gal-1, -4, and -7 in patients with RA and healthy controls and to correlate them with clinical parameters. Methods. Serum samples were collected from patients with RA and healthy donors to determine the serum levels of Gal-1, -4, and -7. Results. Serum levels of Gal-1, -4, and -7 were significantly higher in RA patients compared to controls. We evaluated disease activity (CDAI) with serum levels of galectins and found that patients who were high in disease activity had high levels of galectin compared to the moderate activity group. Galectin-4 had higher levels in patients who were in high activity when compared to the group in remission or low activity. Evaluating the activity of the individual disease (DAS28), patients in high individual activity had high levels of Gal-4 when compared to the group in remission or low activity. We also found an association between positive rheumatoid factor and Gal-1 and Gal-4 levels. Conclusion. Our results show for the first time the relationship between serum levels of galectin and the clinical parameters of patients with RA. Demonstrating their role in pathogenesis, new studies with galectins are needed to assess how they function as a biomarker in RA. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Plný text